Haemophilia therapy has undergone very rapid evolution in the last 10 years. The major limitation of current replacement therapy is the short half-life of factors VIII and IX. These half-lives have been extended by the addition of various moieties, allowing less frequent infusion regimens. Entirely novel approaches have also entered the clinic, including a bispecific antibody that mimics factor VIII and strategies that rebalance the haemostatic mechanism by reducing antithrombin through inhibition of synthesis. These two treatments are available by subcutaneous injection at infrequent intervals and both can be used in patients with neutralising antibodies (inhibitors). Finally, a cure may be on the horizon with preliminary evidence of success for gene therapy in haemophilia B and A.
Haemophilia A and B are X-linked, monogenic bleeding disorders due to deficiency in factor VIII (FVIII) and factor IX (FIX) respectively. Approximately 1/5000 males are affected with haemophilia A, and 1/30 000 males have haemophilia B (Mannucci & Tuddenham, 2001; Bolton-Maggs & Pasi, 2003) . In its severe form, spontaneous bleeding occurs from a young age, typically in the form of haemarthroses and skeletal muscle haematomas in the absence of antecedent trauma, resulting in chronic arthropathy with significant deformities in the long term if untreated. In the pre-clotting factor concentrate era, death in both conditions was primarily due to intracranial haemorrhage or other life-threatening bleeds and patients rarely survived beyond 10 years. Prophylactic administration of factor concentrate to maintain circulating factor levels above 1 iu/dl (1%) of normal has resulted in a dramatic reduction in bleeding frequency and its associated complications, with substantial improvements to life expectancy over recent decades (Darby et al, 2007) .
In the last 40 years, treatment has largely focused on incremental changes, progressing from using cryoprecipitate (for haemophilia A) or whole plasma (for haemophilia A or B) to plasma-derived and, more recently, recombinant specific factor concentrates. Treatment based on cryoprecipitate transfusion was rich in FVIII, and was in routine use until the 1970s (Mannucci, 2002 ). Developments were made to move towards factor concentrates to deliver a more consistent dose compared with cryoprecipitate, as well as significantly improving safety of concentrates through viral inactivation steps by heat, solvent detergent and nanofiltration methods.
Despite significant improvements to ensure safety, there are disadvantages with current clotting factor replacement. Inhibitor formation (neutralising allo-antibodies which form against factor concentrate) causes significant morbidity for patients, and affects 20-45% with severe haemophilia A and 3% of haemophilia B who are previously untreated patients (PUPs) (Astermark et al, 2010; Peyvandi et al, 2016) . Immune tolerance induction (ITI) regimens are used to eradicate the inhibitor, but can take several months or years, and are only effective in haemophilia A. While 80% respond to this treatment with resolution of the inhibitor, ITI is highly expensive as it requires very high doses of concentrate to succeed (50-200 l/kg alternate days or daily) (Collins et al, 2013) . At least 20% of patients are resistant to ITI, with long term consequences for their health due to hitherto only partly successful agents for bypassing FVIII or FIX deficiency in the presence of neutralising antibody. To reduce the risk of inhibitor formation, some haemophilia centres elect to use plasma-derived concentrates for PUPs, as these may have lower inhibitor risks compared with recombinant products. The SIPPET (Survey of Inhibitors in Plasma ProductsExposed Toddlers) study, which recruited children, showed that in PUPs the use of recombinant FVIII had an 87% increase in risk of inhibitor formation rates compared with plasma-derived products (Peyvandi et al, 2016) . However, the use of plasma-derived products does not eliminate the risk of viral transmission nor of prions causing variant Creutzfeldt-Jakob Disease.
Pharmacokinetics in each individual varies and therefore standardised dosing may result in patients being undertreated if factor clearance is higher than expected. In the United Kingdom, routine primary prophylaxis for patients with severe haemophilia A is offered on alternate days, and every 3-4 days for severe haemophilia B. For haemophilia A, FVIII concentrate dosing is recommended on the basis of a half-life of 8-12 h (Srivastava et al, 2013) , but studies of large patient cohorts suggest that FVIII half-life has a much wider range, estimated between 6 and 25 h (Bj€ orkman et al, 2009 (Bj€ orkman et al, , 2010 . Patients with levels which routinely fall below 1 U/dl are at risk of increased bleeding (Collins et al, 2009) . Variation in personal lifestyles or bleeding phenotypes may mean patients require different trough level targets. To account for these variations, clinicians may elect to undertake individualised pharmacokinetic studies, the results of which could reduce costs of treatment with increased frequency of dosing (Collins, 2012) . Caution in interpreting results is required given the challenges with accurate factor level measurement, with differing levels reported between 1-stage and chromogenic assays for standard half-life and extended half-life concentrates .
Factor concentrates remain highly expensive even with national contract negotiation (O'mahony et al, 2015) and stretch national health budgets, while being unaffordable in less economically developed countries. Prophylactic treatment to reduce mortality and improve quality of life is therefore beyond the means of many haemophilia patients across the world. Support for haemophilia patients in the form of regular medical reviews is also lacking in many under-resourced areas.
The last decade of research in haemophilia has yielded many potentially life-changing therapies with exciting novel treatments, such as RNA silencing agents (small interfering RNA, siRNA), FVIII mimetics and gene therapy, which are currently in clinical trials and show great promise. There remains a significant unmet medical need to improve selfcare, reduce requirements for venous access and frequency of dosing, reduce or eliminate inhibitor risk and, ultimately, devise a cure for this condition. In this review, we summarise recent advances in haemophilia treatment and the current clinical progress made in these areas.
Factor concentrates
Half-life extension has been an important evolution in concentrate manufacturing to enable patients to reduce the frequency of dosing with better maintenance of factor levels, especially higher trough levels. This has been more successful in haemophilia B than in haemophilia A (where the half-life is dominated by that of its carrier -von Willebrand Factor, VWF). Table I lists recently licensed FVIII and FIX concentrates or those with completed clinical trials. Historically, standard half-life FVIII concentrates were the first to be commercially available, followed by FIX products but, in recent years, extended half-life (EHL) concentrates for haemophilia B have been developed more quickly, with clinically significant increases over standard half-life FIX concentrates of 2Á4-to 4Á8-fold . Previously published trial data on EHL concentrates has been collated into a review for clinicians to choose an option that would be best suited for their patients as per recommendations issued by the United Kingdom Haemophilia Centres' Doctors' Organisation (Collins et al, 2016) .
FIX concentrates
EHL FIX concentrates have enabled dosing frequency in haemophilia B to be reduced from approximately twice weekly to once every 7-14 days (Collins et al, 2016) . Three FIX products have completed Phase 3 clinical trials in haemophilia B patients, with each using different methods to prolong circulating FIX levels. rFIX-Fc (Alprolix; Biogen, Cambridge, MA, USA) fuses the Fc immunoglobulin region with FIX, while rFIX-FP (Idelvion; CSL Behring, King of Prussia, PA, USA) combines FIX with albumin, and nonacog beta pegol (N9-GP; Novo Nordisk, Bagsvaerd, Denmark) is a pegylated version of FIX. Despite the differing products from a manufacturing perspective, haemostatic efficacy was reported at similar levels, with all three products requiring 1-2 injections for bleed resolution and an overall efficacy of between 96Á7% and 97Á2%. Median annual bleeding rates (ABR) were estimated at between 0 and 3Á0 for all three products (Collins et al, 2014; Santagostino et al, 2016; .
FVIII concentrates
FVIII EHL concentrates have yielded less progress, with halflife prolongation of 1Á5 times compared with standard FVIII concentrates . As with FIX EHL concentrates, Fc fusion or pegylation has been used to produce FVIII EHL concentrates, with half-lives of new products ranging from 14Á3 to 19 h. Because of this modest extension in half-life, subject to pharmacokinetic analysis for individualised dosing, it is recommended to suggest a reduction in frequency of dosing from alternate days to once every 3-4 days (Collins et al, 2016) . The relative lack of improvement in half-life in FVIII concentrates is thought to be related to the interaction of FVIII with VWF. In a few patients, no increase in the interval dosing is seen when an EHL concentrate is used compared with a standard product (Makris, 2012; Tang et al, 2013; Croteau & Neufeld, 2015) .
Manufacturers have continued to produce new versions of recombinant standard half-life concentrates with putative improvements in their manufacturing process. Table II lists the different generations of products and their characteristics. Increasingly, the trend has been towards eliminating human or animal plasma-derived proteins in large scale manufacturing, in order to reduce, as far as possible, risks of (as yet) unidentified viruses to ensure the highest level of safety.
Two new, third generation concentrates have been produced: BAY81-8973 (Kovaltry; Bayer, Leverkeusen, Germany), a full length FVIII, is based on the same sequence as octocog alfa, a second generation concentrate (Kogenate FS; Bayer) but with the removal of human or animal proteins in its manufacture apart from the use of a baby hamster kidney (BHK) cell line (Keating, 2016) . Turoctocog alfa (NovoEight; Novo Nordisk) is a B-domain truncated FVIII, with the B domain specifically designed to accommodate pegylation. The sequence in this FVIII product has been used to develop a pegylated FVIII, Turoctocog alfa pegol (N8-GP; Novo Nordisk) as an EHL concentrate.
Fourth generation concentrates have also been in clinical trials with the aim of reducing inhibitor formation. This differs from third generation concentrates by using human instead of animal cell lines for production, with further potential to reduce immunogenicity. Simoctocog alfa (Nuwiq; Octapharma, Lachen, Switzerland) is currently the only fourth generation, standard half-life concentrate produced with human embryonic kidney (HEK) cells and post-translational modifications are designed to be similar to plasma-derived FVIII. A multicentre, open-label Phase 3 trial in 32 adults in a standard prophylaxis regime for ≥6 months who were severe previously treated patients (PTPs) showed mean ABRs of 2Á28 for all bleeds, 1Á16 for spontaneous bleeds and 1Á00 for traumatic bleeds. Biochemical in vitro analysis showed normal restoration of thrombin generation, and no discrepancy between 1-stage activated partial thromboplastin time-based and chromogenic assays. A further Phase 3 study is still under recruitment for PUPs (Liesner et al, 2016) , however the participation rate had not yet reached the stage of 50 exposure days to inform on inhibitor rates compared with other currently licensed products.
Non-clotting factor-based therapies
Alternative approaches using methods beyond clotting factor replacements have been developed, primarily with the aim of restoring haemostasis through bypassing the deficient coagulation protein. Table III summarises the approaches, of which two methods aim to inhibit proteins that are themselves inhibitors of the coagulation pathways, thus targeting both haemophilia A and B patients (a monoclonal anti-TFPI antibody and a siRNA molecule to reduce antithrombin levels), and the use of an antibody to mimic the activity of FVIII as a co-enzyme for haemophilia A. These alternative approaches have efficacy in patients with inhibitors who do not respond to conventional clotting factor replacement. These newer agents also are amenable to the simpler mode of delivery by subcutaneous injection, eliminating the need for intravenous administration.
Antithrombin targeting
A strategy to rebalance the haemostatic system in patients with haemophilia, who have defective procoagulant Table I . List of new factor VIII/factor IX standard and extended half-life concentrates. Italics denote fourth generation concentrates.
Name of concentrate pathways, works to reduce their natural inhibitor of thrombin generation. Antithrombin (AT, also termed SERPINC1) is a serine proteinase inhibitor in the serpin family, and acts in the coagulation system by primarily inhibiting thrombin, activated factor X (FXa) and activated factor IX (FIXa) through irreversible neutralisation. AT is a key protein in the haemostatic pathway for regulating normal haemostasis, as AT deficiency either in congenital or acquired forms is the highest risk factor for thromboembolic disease (Menache et al, 1992) . Small interfering RNA (siRNA) sequences have been used to target AT by binding with SERPINC1mRNA produced by the hepatocyte. Fitusiran is a double stranded RNA molecule which inhibits and degrades SERPINC1 mRNA and, in turn, reduces AT levels. As AT inhibits FXa, the reduction in AT potentiates the effect of the procoagulant pathway to restore normal haemostasis. A Phase I trial targeting healthy volunteers injected 45 lg/kg doses weekly for 3 weeks and noted a trough AT level at 28 days with an increase in thrombin generation by 334% (Sorensen et al, 2014) .
A completed Phase I dose-escalation study (NCT02035605) was performed looking at four healthy volunteers and 25 patients with moderate or severe haemophilia A or B without inhibitors, at varying doses of administration (healthy volunteers received 0Á03 mg/kg or placebo, while haemophilia participants received 0Á015-0Á075 mg/kg in weekly doses or 0Á225-1Á8 mg/kg or 80 mg in monthly dosing). Initial trial results were promising, with mean maximum AT reduction of 70-89% from baseline and a fall in mean ABR (at all doses) from 9Á7 to 5Á4 at 29-56 days post last dose. Increase in thrombin generation correlated with decreases in AT level, with haemophilia participants who had >75% AT reduction from baseline achieving median peak thrombin levels at the lower end of the range observed in healthy volunteers. No serious adverse events were recorded (Pasi et al, 2017a) . However, in a Phase 1/2 extension study (NCT02554773) a fatal thrombosis was announced by Alnylam in a press release in September 2017. The patient in question, while on fitusiran, had received three doses of FVIII concentrate therapy (31-46 iu/kg each dose) over 3 days for exercise-induced hip pain when he developed a headache after the third dose. The headache was judged to be secondary to a subarachnoid haemorrhage based on computed tomography imaging, and the patient continued to receive FVIII concentrate 2-3 times daily with deterioration in his clinical status until death from cerebral oedema. Further analysis suggested that the precipitating event for the intracranial bleed was because of a cerebral venous sinus thrombosis. All further trials with fitusiran have been suspended while safety investigations are in progress.
TFPI inhibition
Tissue factor pathway inhibitor (TFPI) is a multivalent, Kunitz-type proteinase inhibitor (KPI) with three KPI domains, and functions by inhibiting generation of FXa and the activity of the tissue factor (TF)/FVIIa complex (Broze & Girard, 2012) . Inhibition of TFPI downregulates the negative feedback loop that regulates TF/FVIIa-mediated Factor X (FX) activation during the initiation phase of coagulation. Blockage of TFPI inhibition aims to restore TF/FVIIamediated FXa generation that is sufficient for haemostasis. Concizumab (mAb 2021), a monoclonal antibody was designed to inhibit KPI domain 2 on TFPI, which is known to bind FXa. In a study investigating in vitro and in vivo effects by Hilden et al (2012) , the addition of mAb 2021 to haemophilic plasma and whole blood shortened clot times in a dilute prothrombin time (PT) assay and improved thrombin generation. In a transient rabbit haemophilia model induced by FVIII antibodies, mAb 2021 was given at doses from 0Á5 to 8 mg/kg. Bleeding volumes for doses ≥1 mg/kg reduced bleeding compared with rabbit haemophilia controls, and were not significantly different from normal rabbit controls. At doses of 10 mg/kg, subcutaneous injection in rabbits was also shown to be effective (Hilden et al, 2012) .
A human Phase 1 dose finding study was conducted in both healthy volunteers (n = 28) and haemophilia patients (n = 24) with concizumab injected both intravenously and subcutaneously. Three adverse events were reported in those receiving concizumab, one episode of superficial thrombophlebitis which resolved spontaneously and one of transient proteinuria and another of abdominal pain. No clinically relevant changes in platelets, PT, aPTT, fibrinogen or AT were found. Non-linear pharmacokinetics were noted and a dosedependent procoagulant effect of concizumab was seen as increased levels of D-dimers and prothrombin fragment 1 + 2. No cases of thrombosis were observed (Chowdary et al, 2015) . In a separate ex-vivo spiking study, platelet poor plasma from haemophilia patients was spiked with concizumab. At doses of 10 nmol/l, thrombin generation approached those of healthy controls (Waters et al, 2017) . Two Phase 2 trials investigating the effect of concizumab on haemophilic patients with and without inhibitors (registered trials NCT03196284 and NCT03196297 respectively) are yet to open.
FVIII co-enzyme mimetics
Emicizumab, currently in Phase 3 trials, is a humanised, immunoglobulin G4 (IgG4) antibody designed to have the same functional characteristics as activated FVIII (FVIIIa). The antibody functions in a bispecific format by binding FIXa to one arm of the antibody and FX to the other, accelerating the activation of the FX zymogen to FXa, thus propagating further thrombin generation. The antibody, which closely mimics the activity of FVIIIa, can bypass any inhibitors to FVIII, and carries a further significant advantage as delivery is by subcutaneous injection rather than intravenous infusion.
A Phase I trial with an initial loading dose of 1 mg/kg, followed by one of 0Á3, 1 or 3 mg/kg weekly for 12 weeks was carried out in severe haemophilia A patients with and without inhibitors. In 18 patients (6 at each dose), all dosing levels showed a reduction in median ABR from 32Á5 to 4Á4, 18Á3 to 0 and 15Á2 to 0, respectively. In eight of 11 patients with inhibitors, no bleeding occurred, with an accompanying reduction in use of clotting factors to stop bleeding and no identified antibodies to emicizumab (Shima et al, 2016) .
Phase 3 trials with emicizumab have commenced and are continuing. HAVEN 1 (NCT02622321) has completed recruitment (n = 109) in patients with inhibitors 12 years and older. Patients were divided into three arms (emicizumab, no emicizumab and emicizumab with previous history of bypassing agent prophylaxis). Of the patients on emicizumab, 63% reported no bleeds on the trial, with an overall reduction in bleed rate of 87% compared with the no emicizumab arm, with accompanying improvements in health status and quality of life assessments (P < 0Á001). The bleeding rate fell by 79% in those patients who had previously received prophylactic bypassing agents.
Injection site reactions were reported in 15% of patients receiving the drug. Five patients developed major adverse events during the Phase 3 trial, all with concomitant use of activated protein complex concentrate (aPCC) to stop active bleeds (two episodes of thrombosis and three incidents of thrombotic microangiopathy). One death occurred from the five patients with a major adverse event reported but was judged to be unrelated to emicizumab administration, and two of these five patients successfully restarted emicizumab with no further side effects (Oldenburg et al, 2017) . Preliminary work on characterising the thrombogenicity of emicizumab have started with ROTEM analysis on citrated, whole blood samples of haemophilia patients. Ex-vivo spiking of emicizumab and a bypassing agent (either rFVIIa or aPCC) significantly decreased the clot time and clot formation time (CFT) compared with emicizumab alone, with aPCC showing greater shortening of clot time and CFT compared with rFVIIa (Yada et al, 2017) . This may underline concerns that an unregulated FVIII mimic that functions in a permanently active state produces a deregulated and intrinsically unstable thrombin generation system, with more investigation required on the causes of thrombogenicity. Additional data suggest that emicizumab lacks the ability to function in the absence of phospholipid binding and has a much lower binding affinity compared with FVIII to FIXa and FX which may compensate for the permanently 'switched on' activity. Subsequent trial protocol amendments have prohibited the use of aPCC with emicizumab to prevent further serious adverse events.
More Phase 3 trials are underway, with HAVEN 2 (NCT02795767) targeting inhibitor patients aged <12 years old, and further studies to investigate non-inhibitor patients (HAVEN 3, NCT02847637) and reductions in dosing frequency to fortnightly or monthly (HAVEN 4, NCT03020160).
Gene therapy
A one-time intravenous infusion to treat haemophilia permanently is a paradigm-shifting therapy for patients. Current treatment, because of its expense and pharmacodynamics, has meant that prophylactic factor concentrate treatment had only the modest goal of keeping trough levels of factor just above 1 iu/dl to stop major acute bleeding and its chronic sequelae. Fairly recent data, by the simple but effective means of studying patients with mild haemophilia, clearly demonstrated that bleeding in joints is only completely eliminated at levels of 15 iu/dl or more (den Uijl et al, 2010) .
Even in its extended half-life forms, clotting factor replacement (as described above) requires repeated intravenous infusions, although injections are required less frequently. Replacement factor therapy necessitates interval dosing, which comes with peaks and troughs of factor levels; occasional breakthrough bleeds result when these trough levels are insufficiently high.
Both haemophilia A and B are ideal candidates for gene therapy; a small increase in factor levels can substantially ameliorate the bleeding phenotype. Gene therapy has had a resurgence of interest for its curative potential in many conditions but previously had its setbacks; initial trials in 2002 in severe combined immunodeficiency successfully treated the condition, but the use of an oncoretroviral vector inevitably led to insertion of the transgene into the host genome, which in a tiny proportion of insertions upstream of the LMO2 gene in some recipients caused a leukaemia like syndrome (Thomas et al, 2003) . Safety has therefore been a key concern of subsequent trials since then.
In haemophilia, adeno-associated virus (AAV) is the vector of choice, selected for its lack of pathogenicity in humans in that the majority of viral DNA is not integrated into the host genome and remains episomal, thus reducing likelihood of oncogenesis and germ line transmission. Currently, there remain hypothetical risks to tumourigenesis with AAV gene therapy despite an absence of oncogenic events in over 130 AAV gene therapy studies. Low level of integration has been observed with wild-type AAV viruses, estimated at 0Á1% of virus transduction for chromosome 19-specific integration, a site of known predilection for AAV integration (Huser et al, 2002) . More recent findings have identified clonal integration of AAV2 in hepatocellular carcinoma (HCC) samples in 11 out of 193 cases studied, which have upregulated cancer driver genes (CCNA2, TERT, CCNE1, TNFSF10, KMT2B) (Nault et al, 2015) . Notably among the 11 AAV-positive biopsies, five biopsies presented with other well-known HCC-driving conditions (such as alcohol consumption or hepatitis B or C infections) and four biopsies presented with AAV-unrelated mutations which have been previously linked with liver cancer development (such as TP53 or AXIN1).
Current participants recruited to trials have been limited to adult populations for whom the liver is fully developed, such that effective hepatocyte transduction is not lost in mitotically active and growing liver tissue. Patients identified as suitable for AAV gene therapy must be seronegative for antibodies to the specific capsid used. Anti-AAV antibodies across all serotypes are estimated at 10-80%, but some serotypes, such as AAV5 (10-20%) and AAV8 (10-30%), have less population immunity compared with AAV2 (up to 70%), which has historically been the most frequently studied (Halbert et al, 2006; Calcedo et al, 2009; Mingozzi & High, 2013) , and thus switching capsids may provide a solution to increasing access for patients to gene therapy. A summary of current trials conducted in haemophilia A and B are given in Table IV below.
Haemophilia B
The first successful study in severe haemophilia B patients showed sustained FIX expression in a cohort of 10 patients, while studies prior to this used a variety of vectors resulting in only transient increases in patients' factor levels before returning to baseline (Nathwani et al, 2011 (Nathwani et al, , 2014 Lheriteau et al, 2015) . To overcome difficulties observed in previous trials, the F9 gene was codon optimised, such that the codon sequence of each amino acid was modified to reflect sequences of human proteins that were highly expressed in the human liver. In addition, a F9 self-complementary sequence enabled one virion to have both the coding and complementary sequence such that the transgene can become readily transcriptionally active. Finally, a pseudotyped vector was used with an AAV2 genome but with the AAV8 capsid, which has increased liver tropism and reduced antibody seroprevalence in humans compared with other serotypes of AAV (Boutin et al, 2010; Sands, 2011) .
Patients were enrolled to this Phase I study at low, intermediate and high vector doses, producing sustained FIX coagulant activity (FIX:C) expression at 1-6 iu/dl in all 10 subjects during a follow-up period extending to a median of 6 years, concomitant with decrease in FIX concentrate usage by 90%. The most promising current trial, sponsored by Spark Therapeutics and Pfizer, has used a novel engineered AAV capsid, with a FIX Padua (F9 R338L) transgene which is known to demonstrate 8-fold higher activity and demonstrates a thrombophilic tendency in patients with otherwise normal coagulation states, compared with wild-type FIX (Simioni et al, 2009) . In 10 patients, mean FIX:C levels of 29 iu/dl were achieved in those reaching 12 weeks of followup (George et al, 2016) .
Haemophilia A
Although haemophilia A is five times more prevalent than haemophilia B and therefore the more obvious candidate for gene therapy, the cDNA size of the F8 gene has been a hurdle to developing an expression cassette that is packageable into an AAV vector for FVIII production. The full length F8 cDNA is 7 kilobases (kb) long compared with the F9 cDNA of 1Á5 kb; and a B-domain deleted form of F8 cDNA is 4Á4 kb. Typically, AAV can package up to 4Á6-5 kb, which leaves little room for regulatory elements of the virus (Lheriteau et al, 2015) . Sequences greater than 5 kb in size have been used successfully, but the in vivo potency of the transgene was reduced by 2-to 3-fold (Dong et al, 2008; Chen et al, 2009) . With additional technical challenges to overcome, clinical trials in haemophilia A have thus lagged those of haemophilia B. The transgene used has been either a B-domain deleted or truncated F8 to reduce expression cassette size, with adjustments in the regulatory sequences to further minimise total size. Four trials are currently in the recruitment phase using different capsids and promoters (see Table IV ). BMN270 (BioMarin) has conducted the first trial with an AAV5 capsid containing a B domain deleted F8 sequence (SQ) (NCT02576795). Phase I recruitment has been completed. 15 patients were treated at doses ranging from 6 9 10 12 vector genomes (vg)/kg to 6 9 10 13 vg/kg. Patients that received the highest dose of 6 9 10 13 vg/kg (n = 7)
achieved mean FVIII coagulant activity (FVIII:C) levels of 116-129 iu/dl with durable responses lasting greater than 52 weeks. A subsequent cohort that received a slightly lower dose (4 9 10 13 vg/kg; n = 6) reached 31-42 iu/dl at 12 weeks. Mean ABR changed from 17 to 0 for patients previously on prophylaxis, with mean annualised FVIII infusion rates falling from 139 to 0. 7. All subjects had a grade 1 transient elevation in alanine transaminase, which was resolved with corticosteroids (Pasi et al, 2017b) . Three other trials now recruiting are using different capsid and FVIII variations (NCT03001830, NCT03003533 and NCT03061201).
Therapeutic monitoring strategies
There are existing challenges in current methods of factor level monitoring post-concentrate treatment, which can vary significantly depending on the concentrate and assay used, with inter-laboratory results showing considerable differences (coefficients of variation of 15-26% with chromogenic assays and 12-19% in one stage assays) (Kitchen et al, 2016 . As patients transition to non-clotting factor therapies, treatment monitoring and establishing 'equivalence' to FVIII: C or FIX:C will become an increasing problem, as uncertainty surrounds the issue of how clinicians determine adequate prophylaxis aside from a bleeding history assessment. In FVIIIa mimetics, considerable discrepancy exists between the measurement of their activity by one-stage clotting assays, chromogenic assays and thrombin generation , even as FVIII:C monitoring by chromogenic assay shows a linear relationship with emicizumab concentrations (Adamkewicz et al, 2017) . As anti-TFPI and anti-AT therapies work on a very different part of the coagulation cascade, correlation with a patient's past treatment modalities will be even more complex. Monitoring patients on different therapies will require novel strategies and standardisation. Clinical laboratories will need to adapt to new methods; only then can there be informed assessment of breakthrough bleeding at patient reviews.
Future therapies
Innovative strategies that have not yet reached the stage of clinical trials revolve largely around three areas.
Firstly, in haemophilia A, attempts are being made to extend the half-life of FVIII by improving FVIII-VWF interaction. Previous work has shown that expression or infusion of the D'D3 region of VWF is sufficient to stabilise and prolong half-life of FVIII in VWF knockout mice, with a fusion D'D3 VWF-Fc protein demonstrating significantly longer half-life than a D'D3 synthetic VWF fragment alone (Yee et al, 2014) . By making use of the FVIII-VWF interaction, strategies may be designed to co-infuse recombinant VWF, or FVIII variants with stronger affinity to VWF. Pestel et al (2017) have used recombinant D'D3-albumin fusion protein and co-infused this with FVIII-SingleChain (CSL Behring) into haemophilia knockout mice, rats and rabbits, which improved the half-life of FVIII to at least 1Á5-to 3-fold. Kawecki et al (2017) used a different approach by developing a bivalent nanobody that binds both VWF and albumin, which extends the half-life of VWF by 8-fold and FVIII by 6-fold at 7 days in wild type C57Bl6 mice.
Secondly, work on non-clotting factor replacements to haemophilia have continued. Alternative FVIIIa mimetics are in development, with new alternative binding antibodies similar to emicizumab showing evidence of FXa generation . With the success of AT targeting therapy in clinical trials, Ayme et al (2017) have created anti-AT nanobodies with high binding affinity, which have blocked AT activity by 50-100% and normalised thrombin generation in a haemophilia knockout murine model. The potential of nanobodies with their short transgenic sequences could be used in AAV gene therapy approaches to permanently lower AT levels . Alternatively, Polderdijk et al (2017) targeted a different aspect of the anticoagulant pathway by using a modified a1-antitrypsin to inhibit activated protein C which showed restoration of thrombin generation in three separate mouse models.
Thirdly, modifications to clotting factors to produce hyperfunctional variants may reduce frequency of intravenous injection or enable subcutaneous administration instead. A variant of FIX, termed CB2679d, was developed by Levy et al (2017) with increased affinity for FVIIIa and resistance to AT inhibition, resulting in 20-fold potency increase in vitro and in a haemophilia B dog model in comparison with wild type FIX.
Conclusion
Treatment for haemophilia in the coming years is entering a revolutionary phase, with the advent of multiple treatments coming to market such that factor replacement soon will no longer be the sole option. Approved extended halflife factor concentrates have started to improve the quality of life of patients through reducing injection frequency. Emerging non-factor therapies in trial have the potential to significantly alter the management of patients in the medium term, as clinicians and patients now face the prospect of having many more choices for treating haemophilia and tailoring it to needs and lifestyle of individual patients, with each of the therapies targeting different unmet needs in the haemophilia population. These treatments have already significantly changed the management of patients with inhibitors and offer more convenient choices for non-inhibitor patients with subcutaneous injections on a less frequent basis. Gene therapy offers potential for cure by means of a single treatment. Furthermore, in resource-limited settings, where access to healthcare and factor concentrates is inconsistent, it has obvious advantages. However, it will undoubtedly incur a high cost for initial treatment.
Despite the number of novel therapies in the haemophilia field, standard half-life factor concentrate will remain as a mainstay of treatment over the next years given that these are familiar to patients and have extensive safety data, predictability and ease of monitoring efficacy by using factor assays. For most patients, these treatments are highly effective and they may not feel compelled to alter their treatment to the newer products.
Overall, the emergence of agents with novel modes of action now in Phase 3 trials shows that new treatments are coming ever closer to marketing approval, bringing with them the prospect of highly individualised care in haemophilia as part of the treatment conversation to realise the optimal management that patients and their clinicians wish to achieve.
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